Finally, tau antibody A, which targets the amino-terminal of the tau protein, was less efficacious in the Alzheimer’s disease seeding model than the central epitope tau antibody D, suggesting that as has been demonstrated in cellular systems, targeting the right tau epitope may also be important for in vivo efficacy. This evidence concerns the gene MAPT and Alzheimer disease.